EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Manali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, Gerald Li, Takara Scott, Jeffrey S Ross, Lincoln Pasquina, Richard S P Huang, Heather McArthur, Mia A Levy, Ryon P Graf, Kevin Kalinsky

Breast Cancer Research and Treatment · 2024-10 · 207 (3) · 599-609

DOI: 10.1007/s10549-024-07376-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 14.06.2024. Verfasst von Manali A Bhave und 11 weiteren Autor:innen. Beteiligte Einrichtung: Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Building B, Suite 4000, Atlanta, GA, 30322, USA. manali.ajay.bhave@emory.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, PTEN Phosphohydrolase, Estrogen Receptor alpha, Class I Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment landscape for HR(+)HER2(−) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP) using tissue (TBx) and liquid biopsies (LBx) in HR(+)HER2(−) MBC.

Methods

Records from a de-identified breast cancer clinicogenomic database for patients who underwent TBx/LBx testing at Foundation Medicine during routine clinical care at ~ 280 US cancer clinics between 01/2011 and 09/2023 were assessed. GA prevalence [ ESR1 mut, PIK3CA mut, AKT1 mut, PTEN mut, and PTEN homozygous copy loss ( PTEN loss)] were calculated in TBx and LBx [stratified by ctDNA tumor fraction (TF)] during the first three lines of therapy. Real-world progression-free survival (rwPFS) and overall survival (rwOS) were compared between groups by Cox models adjusted for prognostic factors. Results ~ 60% of cases harbored 1 + GA in 1st-line TBx (1266/2154) or LBx TF ≥ 1% (80/126) and 26.5% (43/162) in LBx TF < 1%. ESR1 mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%). PTEN loss was detected at higher rates in TBx (4.3%) than LBx (1% in TF ≥ 1%). Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor ( n = 573) with ESR1 mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor ( n = 348).

Conclusion

Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines. Reflex TBx should be considered when ctDNA TF < 1%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPTEN PhosphohydrolaseEstrogen Receptor alphaClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansFemaleMiddle AgedAgedPrognosisAdultMutationNeoplasm MetastasisReceptors, EstrogenAntineoplastic Agents, HormonalGenomicsReceptors, ProgesteronePrevalence

Stichwörter der Autor:innen

AKT inhibitorESR1Genomic sequencingHR(+)HER2(−)Metastatic breast cancer

Substanzen

PTEN PhosphohydrolaseEstrogen Receptor alphaClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorReceptors, EstrogenAntineoplastic Agents, HormonalReceptors, ProgesteronePIK3CA protein, human

Autor:innen und Institutionen

  • Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Building B, Suite 4000, Atlanta, GA, 30322, USA. manali.ajay.bhave@emory.edu.
  • Foundation Medicine, Inc, 400 Summer Street, Boston, MA, 02210, USA. jquintanilha@foundationmedicine.com.
  • Foundation Medicine, Inc, 400 Summer Street, Boston, MA, 02210, USA.
  • Upstate Medical University, Syracuse, NY, USA.
  • University of Texas Southwestern, Dallas, TX, USA.
  • Rush University Medical Center, Chicago, IL, USA.

Förderung

  • Foundation Medicine

Zitieren

APA

Bhave, M. A., Quintanilha, J. C. F., Tukachinsky, H., Li, G., Scott, T., Ross, J. S., Pasquina, L., Huang, R. S. P., McArthur, H., Levy, M. A., Graf, R. P., & Kalinsky, K. (2024). Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Research and Treatment, 207(3), 599-609. https://doi.org/10.1007/s10549-024-07376-w

Vancouver

Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Research and Treatment. 2024;207(3):599-609. doi:10.1007/s10549-024-07376-w

BibTeX
@article{Bhave2024,
  author = {Bhave, Manali A and Quintanilha, Julia C F and Tukachinsky, Hanna and Li, Gerald and Scott, Takara and Ross, Jeffrey S and Pasquina, Lincoln and Huang, Richard S P and McArthur, Heather and Levy, Mia A and Graf, Ryon P and Kalinsky, Kevin},
  title = {Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  volume = {207},
  number = {3},
  pages = {599--609},
  doi = {10.1007/s10549-024-07376-w}
}
Kostenlos starten →